3/31
11:24 pm
sgmo
???????????2035????702.2???????????????(CAGR)22.78%??? [CNET News]
Low
Report
???????????2035????702.2???????????????(CAGR)22.78%??? [CNET News]
3/31
07:20 am
sgmo
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results [Yahoo! Finance]
3/30
11:07 pm
sgmo
Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
3/30
08:30 pm
sgmo
Sangamo Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/30
04:01 pm
sgmo
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
High
Report
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
3/30
10:00 am
sgmo
Here are the major earnings after the close Monday [Seeking Alpha]
Medium
Report
Here are the major earnings after the close Monday [Seeking Alpha]
3/19
04:55 pm
sgmo
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call [Yahoo! Finance]
3/19
04:03 pm
sgmo
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
Low
Report
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
3/9
08:22 am
sgmo
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease [Yahoo! Finance]
3/9
08:05 am
sgmo
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Medium
Report
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
2/10
08:05 am
sgmo
Sangamo Therapeutics (NASDAQ:SGMO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Sangamo Therapeutics (NASDAQ:SGMO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
2/3
06:05 pm
sgmo
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 [Yahoo! Finance]
2/3
04:05 pm
sgmo
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
Medium
Report
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
2/3
09:10 am
sgmo
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
High
Report
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
1/31
01:33 am
sgmo
Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at
Wall St
High
Report
Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at
Wall St
1/23
07:09 pm
sgmo
How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO) [Yahoo! Finance]
Low
Report
How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO) [Yahoo! Finance]
1/12
04:40 am
sgmo
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update [Yahoo! Finance]
Low
Report
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update [Yahoo! Finance]